title: A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.
abstract: Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had > or = 4-fold increases in hemagglutination-inhibition antibody, and 79% had > or = 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults. Trial registration. ClinicalTrials.gov identifier: NCT00110279 .
authors.affiliation: Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. rkarron@jhsph.edu
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Karron
authors.forename: Karen
authors.initials: K
authors.lastname: Callahan
authors.forename: Catherine
authors.initials: C
authors.lastname: Luke
authors.forename: Bhagvanji
authors.initials: B
authors.lastname: Thumar
authors.forename: Josephine
authors.initials: J
authors.lastname: McAuliffe
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Schappell
authors.forename: Tomy
authors.initials: T
authors.lastname: Joseph
authors.forename: Kathleen
authors.initials: K
authors.lastname: Coelingh
authors.forename: Hong
authors.initials: H
authors.lastname: Jin
authors.forename: George
authors.initials: G
authors.lastname: Kemble
authors.forename: Brian R
authors.initials: BR
authors.lastname: Murphy
authors.forename: Kanta
authors.initials: K
authors.lastname: Subbarao
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D004334:Drug Administration Schedule; D006801:Humans; D053127:Influenza A Virus, H9N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated